Lidocaine-magnesium blood cardioplegia was equivalent to potassium blood cardioplegia in left ventricular function of canine heart.
This study evaluated the effects of lidocaine-magnesium blood cardioplegia on left ventricular function compared with potassium blood cardioplegia. Crystalloid cardioplegia which contains lidocaine has been reported but blood cardioplegia is rare. Thirteen dogs received 60 min of global ischemia under hypothermic cardioplumonary bypass (30 degrees C). Potassium blood cardioplegia was administered every 20 min in group A (n=6), and lidocaine-magnesium blood cardioplegia in group B (n=7). We compared the ratio of Emax obtained during IVC occlusion at pre- and post-global ischemia (%Emax) and LVSW (%LVSV). Cardiac function was evaluated prior to CPB and 60 min after reperfusion. There was no difference in time required for cardiac arrest between the two groups (group A: 78+/-3 s, group B: 89+/-9 s). Percentage maximal elastance was significantly better in group B (group A: 63+/-3%, group B: 76+/-4%, P<0.05). Percentage tissue water content of the myocardium after CPB was significantly lower in group B (group A: 82.3+/-4%, group B: 75.5+/-2%, P<0.05). Lidocaine-magnesium blood cardioplegia was equivalent to potassium blood cardioplegia in systolic left ventricular function and reduced myocardial edema in canine heart.
Yamaguchi
Shohjiro
S
Department of General and Cardiothoracic Surgery, Kanazawa University School of Medicine, Takaramachi 13-1, Kanazawa 920-8641, Japan. gucci-s@ya2.so-net.ne.jp
Watanabe
Go
G
Tomita
Shigeyuki
S
Tabata
Shigeki
S
D000818:Animals; D002314:Cardioplegic Solutions / Q000494:pharmacology* / Q000627:therapeutic use; D002315:Cardiopulmonary Bypass / Q000009:adverse effects*; D003326:Coronary Circulation / Q000187:drug effects; D004285:Dogs; D004489:Edema, Cardiac / Q000209:etiology / Q000473:pathology / Q000503:physiopathology / Q000517:prevention & control*; D004548:Elasticity; D006324:Heart Arrest, Induced / Q000379:methods*; D006352:Heart Ventricles / Q000473:pathology / Q000503:physiopathology; D008012:Lidocaine / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D017616:Magnesium Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D009206:Myocardium / Q000473:pathology; D017680:Potassium Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D026941:Sodium Channel Blockers / Q000097:blood / Q000494:pharmacology* / Q000627:therapeutic use; D013599:Systole; D013997:Time Factors; D016277:Ventricular Function, Left / Q000187:drug effects*
D002314:Cardioplegic Solutions; D017616:Magnesium Compounds; D017680:Potassium Compounds; D026941:Sodium Channel Blockers; D008012:Lidocaine